Drug Trial Radar · NCT02030990
The Use of MMC During PRK and Its Effect on Postoperative Topical Steroid Requirements
Last checked: Nov 19, 2026Latest source record: Apr 15, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
300
Planned (sponsor's estimate)
Start
Aug 2014
Primary completion
Jan 2023
Study completion Jul 2023
Sponsor
- Lead sponsor
- United States Naval Medical Center, San DiegoFederal agency
- Sponsor type
- Federal agency
- First posted
- Jan 9, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (care provider)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 21 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
1. Purpose To evaluate the use of mitomycin-C (MMC) as an intraoperative adjunct during photorefractive keratectomy (PRK), its effect on postoperative healing and its ability to reduce the postoperative topical steroid course after the surgery. 2. Research Design This is a single-center, prospective, comparative cohort study. 3. Hypothesis There will not be a significant difference in the refractive corrections amongst the treatment groups, 12 months after surgery. 4. Objectives The primary study objective is to compare the effect of intraoperative MMC and a postoperative short topical steroid taper of 3 weeks, intraoperative MMC and a rapid topical steroid taper of 1 week, and a more commonly accepted postoperative regimen of a 2 month long topical steroid taper without any intraoperative MMC. The primary endpoint evaluated will be objective estimates of refractive error (WaveScan WaveFront™ System) at 12 months post-surgery. Secondarily, the extent of haze formation will be evaluated objectively using densitometry maps generated by automated Scheimpflug imaging of the cornea (Pentacam®). Furthermore, the subjective vision from the patients' perspective will be evaluated by questionnaires.
Conditions
- Corneal Opacity
Interventions
Mitomycin-CDrug
0.01% applied to cornea with a sponge during PRK
Fluorometholone 1% topical ocular steroidDrug
topical steroid drops applied to the cornea after PRK
Primary outcomes
What the sponsor says the trial is designed to measure.
- Refractive ErrorTime frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Navy Warfighter Refractive Surgery Center
San Diego, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.